Core Insights - Evaxion A/S is a clinical-stage TechBio company focused on developing AI-Immunology™ powered vaccines and will present updates at various conferences in the latter half of 2025 [1][3][7] Company Updates - The company will engage with stakeholders and potential partners at multiple conferences across the US, Europe, and Asia to explore business partnerships and scientific collaborations [2][5] - Evaxion is particularly excited about presenting two-year clinical data for its personalized cancer vaccine EVX-01 at the ESMO congress in October 2025 [3][5] Conference Participation - Evaxion's conference schedule includes: - Vaccine Congress, September 7-10, Kyoto - HC Wainwright Global Investment Conference, September 8-10, New York - ESCMID Conference on vaccines, September 10-13, Lisbon - Lake Street Best Ideas Growth Conference, September 12, New York - HC Andersen seminar, September 18, Copenhagen - Vax On Vaccines: Present and future in oncology, October 1, Milan - BiotechX Europe, October 6-8, Basel - World Vaccine Congress Europe, October 14-16, Amsterdam - ESMO Congress 2025, October 17-21, Berlin - Society for Immunotherapy of Cancer (SITC) 2025, November 5-9, National Harbor - Vaccines Summit, November 13-15, Boston - NextGen Omics, November 13-14, London [5][6] Company Background - Evaxion utilizes its proprietary AI platform, AI-Immunology™, to develop novel immunotherapies targeting cancer, bacterial diseases, and viral infections, aiming to transform patient care with innovative treatment options [6][7]

NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 at the upcoming 15th International Congress of Inborn Errors of Metabolism (ICIEM) being held September 2-6, 2025 in Kyoto, Japan. Details for the presentations are as follows: Session: Oral PresentationTitle ...

BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo Healthcare Conference on Wednesday, Septemb ...

BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 ...

Core Points - Sempra Infrastructure and EQT Corporation have signed a 20-year sales and purchase agreement for the supply of 2 million tonnes per annum (Mtpa) of liquefied natural gas (LNG) from the Port Arthur LNG Phase 2 project [1][2] - The agreement is aimed at enhancing U.S. energy exports and supporting global energy security while promoting lower-carbon solutions [2] - The Port Arthur LNG Phase 2 project is expected to have a total liquefaction capacity of approximately 26 Mtpa, doubling the capacity from Phase 1 [5] Company Developments - Sempra Infrastructure has secured all major permits for the Port Arthur LNG Phase 2 project, including project approval from the Federal Energy Regulatory Commission and export authorization from the U.S. Department of Energy [3] - Bechtel has been selected for the engineering, procurement, and construction of the Port Arthur LNG Phase 2 facility, with a final investment decision targeted for 2025 [4] - The project has already attracted interest from other buyers, including a 20-year SPA with JERA Co., Inc. for 1.5 Mtpa and an expanded alliance with ConocoPhillips for 4 Mtpa [2] Industry Context - The Port Arthur LNG Phase 2 project is strategically positioned to meet global energy demand and is part of a broader effort to fortify America's role as a leading energy exporter [2] - The project aligns with the U.S. government's goals of enhancing energy security and supporting local economic development through natural gas projects [2]

Company Overview - Alignment Healthcare, Inc. is focused on providing high-quality, low-cost care for its Medicare Advantage members, emphasizing a mission-driven approach to senior care [2] - The company utilizes a customized care model, a 24/7 concierge care team, and proprietary technology named AVA to deliver coordinated care [2] Upcoming Events - Alignment Healthcare will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 8:30 a.m. EDT [3] - The company will also participate in the Baird 2025 Global Healthcare Conference on September 10, 2025, at 12:15 p.m. EDT [3] Corporate Values - Alignment Healthcare prioritizes its core values of serving with a heart and putting seniors first as it expands its national footprint [2]

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025 Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET 2025 Wells Fargo Healthcare ConferenceFireside chat on Friday, September 5, 2025, at 8:45 a ...

Core Insights - RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases [2] Group 1: Company Overview - RAPT Therapeutics specializes in discovering, developing, and commercializing novel therapies aimed at modulating immune responses related to inflammatory and immunological diseases [2] - The company leverages proprietary expertise in immunology to create innovative treatment options for patients [2] Group 2: Upcoming Events - RAPT management will participate in several investor conferences in September 2025, including: - 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ET [3] - Cantor Global Healthcare Conference on September 4, 2025, at 1:00 p.m. ET [3] - H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 9:00 a.m. ET [3] - Stifel 2025 Virtual Immunology & Inflammation Forum on September 15, 2025, at 9:30 a.m. ET [3] - Live webcasts and archived recordings of these events will be available on the RAPT Therapeutics website [1]

Company Overview - Axogen, Inc. (NASDAQ: AXGN) is a leader in developing and marketing surgical solutions aimed at restoring peripheral nerve function [3] - The company focuses on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair [3] - Axogen's mission is to help restore peripheral nerve function and improve the quality of life for patients with nerve damage through innovative and clinically proven solutions [3] Product Portfolio - Axogen's product offerings include: - **Avance Nerve Graft**: A processed human nerve allograft for bridging severed peripheral nerves [4] - **Axoguard Nerve Connector**: An extracellular matrix coaptation aid for tensionless repair of severed nerves [4] - **Axoguard Nerve Protector**: A product used to wrap and protect damaged nerves while minimizing soft tissue attachments [4] - **Axoguard HA+ Nerve Protector™**: A next-generation technology designed to enhance nerve gliding and provide protection for peripheral nerve injuries [4] - **Axoguard Nerve Cap**: A product to protect nerve ends and reduce the development of painful neuromas [4] - **Avive+ Soft Tissue Matrix™**: An amniotic membrane allograft used to protect and separate tissues during healing [4] - The product portfolio is available in multiple countries including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [4] Upcoming Investor Conferences - Axogen management is scheduled to participate in several investor conferences: - **Cantor Global Healthcare Conference**: Fireside chat on September 3, 2025 [1] - **Wells Fargo Healthcare Conference**: 1x1 investor meetings on September 4, 2025 [2] - **Morgan Stanley Annual Global Healthcare Conference**: 1x1 investor meetings on September 10, 2025 [2] - **Lake Street Best Ideas Growth (BIG 9) Conference**: 1x1 investor meetings on September 11, 2025 [2] - Webcast events will be accessible live and archived for 90 days on Axogen's investor page [2]

Core Viewpoint - Fusion Fuel Green PLC will release an Investor Update Presentation and Video on September 17, 2025, to provide updates on financial results and strategic developments [1][2]. Company Overview - Fusion Fuel Green PLC (NASDAQ: HTOO) specializes in integrated energy engineering, distribution, and green hydrogen solutions through its Al Shola Gas and BrightHy Solutions platforms [3]. - The company operates in the LPG supply and hydrogen solutions sectors, supporting decarbonization across industrial, residential, and commercial sectors [3]. - Fusion Fuel is headquartered in Ireland and has operations in Europe and the Middle East [3]. Upcoming Events - The Investor Update Presentation and Video will be available on the company's Investors page on its website [2]. - Management will discuss updates on the company's activities in Al Shola Gas and BrightHy Solutions, along with other strategic developments [2].